Dr. Reddy's Laboratories is living through the quarter the market both expected and feared: the first unflattering look at the franchise after lenalidomide stopped carrying North America. The June print is not a demand story. It is a quality-and-mix story. A rejected peptide batch turned the company's most important new product into an inventory charge, and the same Hyderabad biologics campus that is supposed to launch the lead biosimilar collected another inspection observation letter. The equity debate is whether this is a one-quarter stumble on a still-growing branded base or a signal that the post-generics engines are not ready to replace the oncology windfall.
Consolidated sales were $853 million. That is a mid-single-digit decline from the year-ago quarter even as the base business, stripped of lenalidomide, grew at a double-digit clip in every major geography. Reported earnings before interest, tax, depreciation and amortization came in at $107 million. The margin is about thirteen percent, versus the high-twenties print a year earlier when lenalidomide still dominated the mix. A $25 million provision for out-of-specification semaglutide active ingredient sits inside that collapse, and solvent and freight costs tied to the Middle East conflict took another roughly one point of margin. Strip those items and management's own bridge still only gets back to the mid-teens, not to the neighborhood of twenty percent the company continues to describe as the full-year aspiration excluding the peptide.
North America still contributes about a quarter of sales, but the region is no longer the profit engine. India, emerging markets and the acquired nicotine-replacement brands now supply more than half of revenue and almost all of the stability. The next two quarters decide whether semaglutide supply resumes on the November timetable and whether the December review date on intravenous abatacept survives another Bachupally inspection cycle. If both slip, the American depositary receipt is a branded-generics compounder trading as if the peptide and biosimilar options still have near-term cash value.